Literature DB >> 15519253

Serum adiponectin levels in adult growth hormone deficiency and acromegaly.

Izumi Fukuda1, Naomi Hizuka, Yukiko Ishikawa, Emina Itoh, Kumiko Yasumoto, Yuko Murakami, Akira Sata, Junko Tsukada, Makiko Kurimoto, Yumiko Okubo, Kazue Takano.   

Abstract

Atherosclerosis and insulin resistance are common complications of adult growth hormone deficiency (GHD) and acromegaly. Circulating adiponectin, an adipocyte-derived protein, has both anti-atherogenic and insulin-sensitising effects. In this study, we measured serum adiponectin levels in patients with either adult GHD or acromegaly to clarify the impact of GH secretory states on the regulation of serum adiponectin levels. Serum adiponectin level was measured by radioimmunoassay in 32 patients with adult GHD, 49 patients with acromegaly and 25 normal subjects. The relationships between adiponectin and insulin sensitivity index assessed as quantitative insulin sensitivity check index (QUICKI), BMI, and serum GH and IGF-I levels were then investigated. The values of QUICKI were significantly lower in patients with acromegaly or adult GHD compared to normal subjects (0.33 +/- 0.03, P < 0.01, 0.35 +/- 0.04, P < 0.05 and 0.36 +/- 0.01, respectively). While patients with adult GHD had significantly lower serum adiponectin levels than patients with acromegaly (6.5 +/- 3.9, 9.2 +/- 5.0, P < 0.01) these levels were not significantly different from those found in normal subjects (7.8 +/- 4.3 mug/ml). There was an inverse correlation between serum adiponectin levels and BMI in both patient groups (GHD r = -0.39, P < 0.05; Acromegaly r = -0.35, P < 0.05). However, serum adiponectin levels correlated positively with QUICKI (R(s) = 0.37, P < 0.05) only in patients with adult GHD. In patients with acromegaly, the levels of circulating adiponectin showed an inverse correlation with serum IGF-I levels (R(s) = -0.34, P < 0.05), but not with basal GH levels. These results demonstrate that adiponectin levels are significantly lower in patients with adult GHD than in patients with acromegaly. Adiponectin levels are similar in patients with GHD and healthy controls, whereas in patients with acromegaly, insulin resistance appears to be not closely related to adiponectin levels compared with BMI. The different relationship between adiponectin and QUICKI observed in the adult GHD and acromegaly groups presumably reflects differences in the mechanisms of insulin resistance under states of GH deficiency or excess.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15519253     DOI: 10.1016/j.ghir.2004.06.005

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  9 in total

1.  Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.

Authors:  H Makimura; T L Stanley; C Y Chen; K L Branch; S K Grinspoon
Journal:  Growth Horm IGF Res       Date:  2011-04-30       Impact factor: 2.372

2.  Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe deficiency adult growth hormone deficiency.

Authors:  Daniel González-Duarte; Ainara Madrazo-Atutxa; Alfonso Soto-Moreno; Alfonso Leal-Cerro
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 3.  Growth hormone and adipose tissue: beyond the adipocyte.

Authors:  Darlene E Berryman; Edward O List; Lucila Sackmann-Sala; Ellen Lubbers; Rachel Munn; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2011-04-05       Impact factor: 2.372

4.  Adipokine profile and urinary albumin excretion in isolated growth hormone deficiency.

Authors:  Carla R P Oliveira; Roberto Salvatori; Rafael A Meneguz-Moreno; Manuel H Aguiar-Oliveira; Rossana M C Pereira; Eugênia H A Valença; Vanessa P Araujo; Natália T Farias; Débora C R Silveira; Jose G H Vieira; Jose A S Barreto-Filho
Journal:  J Clin Endocrinol Metab       Date:  2009-12-16       Impact factor: 5.958

Review 5.  Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans.

Authors:  Michael M Swarbrick; Peter J Havel
Journal:  Metab Syndr Relat Disord       Date:  2008-06       Impact factor: 1.894

Review 6.  A Functional Interplay between IGF-1 and Adiponectin.

Authors:  Stefania Orrù; Ersilia Nigro; Annalisa Mandola; Andreina Alfieri; Pasqualina Buono; Aurora Daniele; Annamaria Mancini; Esther Imperlini
Journal:  Int J Mol Sci       Date:  2017-10-14       Impact factor: 5.923

Review 7.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

8.  Serum Levels of Asprosin, a Novel Adipokine, Are Significantly Lowered in Patients with Acromegaly.

Authors:  Xiaoan Ke; Lian Duan; Fengying Gong; Yuelun Zhang; Kan Deng; Yong Yao; Linjie Wang; Hui Pan; Huijuan Zhu
Journal:  Int J Endocrinol       Date:  2020-12-14       Impact factor: 3.257

Review 9.  Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile.

Authors:  Balázs Ratku; Veronika Sebestyén; Annamária Erdei; Endre V Nagy; Zoltán Szabó; Sándor Somodi
Journal:  Pituitary       Date:  2022-02-01       Impact factor: 4.107

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.